Which of the following drugs are tyrosine kinase inhibitors that target BRAF kinase leading to cell cycle arrest and cancer cell death?

The two drugs that specifically target BRAF kinase and act as tyrosine kinase inhibitors are Dabrafenib and Vemurafenib. Both of these medications are used in the treatment of cancers with BRAF mutations, particularly melanoma.

Dabrafenib is designed to inhibit the activity of the mutated BRAF protein, which is often involved in driving the growth and proliferation of cancer cells. By blocking this kinase, Dabrafenib can induce cell cycle arrest, preventing cancer cells from dividing and leading to their eventual death. Vemurafenib operates similarly, targeting the same BRAF mutations and demonstrating effectiveness in reducing tumor size and improving outcomes for patients with BRAF-mutant cancers.

The other choices consist of drugs that inhibit different kinases or are used in different therapeutic contexts. This makes them unsuitable for the specific action described in the question regarding targeting BRAF kinase.